FUNDING
Coverage Timeline
newest first- Aug 28, 2026FUNDINGOwner Raises $240M at $2.3B to Run Local Businesses$240M at $2.3B→
- Aug 11, 2026FUNDINGVaderis Raises $152M Series B for Rare Disease Trial$152.5M Series B→
- Jul 29, 2026IPOGoldman-Backed Attovia Seeks $212.5M in Biotech IPO$212.5M IPO→
- Jul 13, 2026FUNDINGHelsing Raises $1.8B, Europe's Biggest Defense Round$1.8B at $18B→
All Coverage
FUNDING$240M at $2.3B
Owner Raises $240M at $2.3B to Run Local Businesses
Owner, the AI platform that runs websites, ordering, marketing and phone support for restaurants, raised $240 million led by Growth Equity at Goldman Sachs Alternatives at a $2.3 billion valuation.
DEEP DIVE
FUNDING
Vaderis Raises $152M Series B for Rare Disease Trial
FUNDING$152.5M Series B
Vaderis Raises $152M Series B for Rare Disease Trial
Vaderis Therapeutics closed an oversubscribed $152.5 million Series B co-led by Goldman Sachs Alternatives and TCGX to fund a global Phase 3 trial of its drug for a rare blood vessel disorder.
DEEP DIVE
IPO
Goldman-Backed Attovia Seeks $212.5M in Biotech IPO
IPO$212.5M IPO
Goldman-Backed Attovia Seeks $212.5M in Biotech IPO
Attovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.
FUNDING
Helsing Raises $1.8B, Europe's Biggest Defense Round
FUNDING$1.8B at $18B
Helsing Raises $1.8B, Europe's Biggest Defense Round
Munich-based Helsing closed a $1.8 billion Series E at an $18 billion valuation, Europe's biggest-ever defense-tech round, with Goldman Sachs Alternatives, CPPIB and JPMorgan joining as new investors amid oversubscribed demand.